메뉴 바로가기
주메뉴 바로가기
컨텐츠 바로가기

R&D

Pipeline

Pipeline overview

Three H Bio (3H Bio) Co., Ltd., a Korean bio-venture company established in 2019. 3H Bio develops Obesity Vaccine (3HOTP) candidate and a series of first-in-class drugs for metabolic diseases, including Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). Also, an organoid-based Developmental And Reproductive Toxicity (DART) drug-screening platform technology is under development.

3H Bio provides an exciting in-licensing opportunity for worldwide companies seeking new anti-obesity drugs and the drugs for metabolic syndromes related with lipid metabolism.

Drug development

Indication Program Discovery Non GMP study IND Phase1
Obesity 3HOTP (Human)
3HOTP (Veterinary)
T2DM 3HDTV
NAFLD 3HHTA

Toxicology evaluation platform

Project Proof-of-concept Clinical evaluation Marketing approval
Organoid-based prenatal
tox evaluation platform